Ciro Indolfi to Middle Aged
This is a "connection" page, showing publications Ciro Indolfi has written about Middle Aged.
Connection Strength
0.102
-
Differences in coagulopathy indices in patients with severe versus non-severe COVID-19: a meta-analysis of 35 studies and 6427 patients. Sci Rep. 2021 05 17; 11(1):10464.
Score: 0.015
-
Fast-track ruling in/out SARS-CoV-2 infection with rapid 0/1.5 h molecular test in patients with acute coronary syndromes. J Cardiovasc Med (Hagerstown). 2020 12; 21(12):975-979.
Score: 0.015
-
Impact of cardiovascular risk profile on COVID-19 outcome. A meta-analysis. PLoS One. 2020; 15(8):e0237131.
Score: 0.014
-
Delayed flow-mediated vasodilation and critical coronary stenosis. J Investig Med. 2018 06; 66(5):1-7.
Score: 0.012
-
Migration of a stent from left main and its retrieval from femoral artery: A case report. Medicine (Baltimore). 2017 Dec; 96(50):e9281.
Score: 0.012
-
Intensive cardiac care unit admission trends during the COVID-19 outbreak in Italy: a multi-center study. Intern Emerg Med. 2021 11; 16(8):2077-2086.
Score: 0.004
-
Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era. Eur Heart J. 2020 06 07; 41(22):2083-2088.
Score: 0.004
-
Two-year clinical outcomes of the "Italian diffuse/multivessel disease absorb prospective registry" (IT-DISAPPEARS). Int J Cardiol. 2019 09 01; 290:21-26.
Score: 0.003
-
Evaluation of cardiac function by global longitudinal strain before and after treatment with sofosbuvir-based regimens in HCV infected patients. BMC Infect Dis. 2018 Oct 16; 18(1):518.
Score: 0.003
-
Predictors of bioresorbable scaffold failure in STEMI patients at 3 years follow-up. Int J Cardiol. 2018 Oct 01; 268:68-74.
Score: 0.003
-
Integration of "Omics" Strategies for Biomarkers Discovery and for the Elucidation of Molecular Mechanisms Underlying Brugada Syndrome. Proteomics Clin Appl. 2018 11; 12(6):e1800065.
Score: 0.003
-
Low-dose anticoagulation after isolated mechanical aortic valve replacement with Liva Nova Bicarbon prosthesis: A post hoc analysis of LOWERING-IT Trial. Sci Rep. 2018 05 30; 8(1):8405.
Score: 0.003
-
Incidence, Clinical Presentation, and Predictors of Clinical Restenosis in Coronary Bioresorbable Scaffolds. JACC Cardiovasc Interv. 2017 09 25; 10(18):1819-1827.
Score: 0.003
-
One-year clinical results of the Italian diffuse/multivessel disease ABSORB prospective registry (IT-DISAPPEARS). EuroIntervention. 2017 Jul 20; 13(4):424-431.
Score: 0.003
-
Use of the Instantaneous Wave-free Ratio or Fractional Flow Reserve in PCI. N Engl J Med. 2017 05 11; 376(19):1824-1834.
Score: 0.003
-
Comparative assessment of "plaque/media" change on three modalities of IVUS immediately after implantation of either everolimus-eluting bioresorbable vascular scaffold or everolimus-eluting metallic stent in Absorb II study. Int J Cardiovasc Imaging. 2017 Apr; 33(4):441-449.
Score: 0.003